|
Rubicon Research Repository >
Rubicon Foundation Archive >
Undersea and Hyperbaric Medicine Journal >
Please use this identifier to cite or link to this item:
http://archive.rubicon-foundation.org/8030
|
| Title: | Clinical case report: treatment of a central retinal vein occlusion with hyperbaric oxygen. |
| Authors: | Wright, JK
Franklin, B
Zant, E |
| Keywords: | hyperbaric oxygenation
retinal central vein occlusion
case report
ischemic retina
vision
eye
adjunctive therapy |
| Issue Date: | 2007 |
| Publisher: | Undersea and Hyperbaric Medical Society |
| Citation: | Undersea Hyperb Med. 2007 Sep-Oct;34(5):315-9. |
| Abstract: | A case of retinal central vein occlusion (CRVO) in a 43-year-old man is presented in which hyperbaric oxygen (HBO2) was used as the only treatment method. CRVO is a relatively common cause of visual loss, with hypertension, diabetes, glaucoma and hypercoagulable conditions identified as risk factors. The patient in this report had none of these risk factors and declined treatments other than hyperbaric oxygen. HBO2 was effective in sustaining the ischemic retina and controlling retinal edema until the retina revascularized and vision stabilized. The initial visual acuity in the left eye was 20/200 (corrected), and after two hyperbaric treatments it was 20/30 (corrected). Following three months of HBO2 treatments the vision stabilized to 20/20 (corrected) in the affected eye. Treatment considerations in using HBO2 as adjunctive therapy for CRVO are early institution of treatment, and continuation of HBO2 until the retinal edema has resolved and vision has stabilized. |
| Description: | Undersea & Hyperbaric Medicine : Journal of the Undersea and Hyperbaric Medical Society, Inc. |
| URI: | http://archive.rubicon-foundation.org/8030 |
| ISBN: | 1066-2936 |
| Appears in Collections: | Undersea and Hyperbaric Medicine Journal
|
Files in This Item:
| File |
Description |
Size | Format |
|---|
| 18019081.pdf | | 759Kb | Adobe PDF | View/Open |
|
All items in DSpace are protected by copyright, with all rights reserved.
|
